🇺🇸 FDA
Pipeline program

Bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC), Sofosbuvir / Velpatasvir

AT-01B-008

Phase 3 small_molecule active

Quick answer

Bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC), Sofosbuvir / Velpatasvir for Chronic Hepatitis C Virus (HCV) Infection is a Phase 3 program (small_molecule) at Atea Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Atea Pharmaceuticals
Indication
Chronic Hepatitis C Virus (HCV) Infection
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials